Assembly Bio (ASMB): Net earnings per share for the last 12 months

Symbol and logo of brand Assembly Biosciences, Inc. (ASMB)

The market for hepatitis B and D therapies is experiencing a shortage of effective treatment methods. Assembly Biosciences (ASMB) is addressing this issue by advancing innovative developments with financial support from Gilead Sciences. The TTM annual earnings per share metric visualizes the dynamics of this process, where the -0.07 mark reflects the current state. Strict patents and costly clinical trials ensure a high barrier to entry in this niche.

ASMB (Assembly Biosciences) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/10/2026

Summary analytical data breakdowns for Assembly Bio (ASMB)

- stock price and consensus target price:
Stock Price Assembly Biosciences|ASMB - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Assembly Biosciences, Inc.|ASMB - Total Company Value
- balance sheet net asset value indicators:
Book Value per Share Assembly Biosciences|ASMB - Total Stockholders' Equity|Market Value to Book Value Ratio assemblybio.com|ASMB - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital Assembly Biosciences|ASMB - Long-Term Debt to Capital|Short-Term Debt to Equity Assembly Biosciences Inc|ASMB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Assembly Biosciences, Inc.|ASMB - Long-Term Debt Volume|Company Short-Term Debts Assembly Biosciences|Quick Liquidity assemblybio.com
- net income and valuation multiples indicators:
ASMB - Net Income|Projected Future Earnings Assembly Biosciences|ASMB - Price to Earnings Ratio|Future Price to Earnings Assembly Biosciences, Inc.|ASMB - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Assembly Biosciences, Inc.|ASMB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Assembly Biosciences|ASMB - Earnings per share for the trailing year|Quarterly EPS earnings growth assemblybio.com|ASMB - Earnings per share growth in current year|Earnings growth forecast for next year Assembly Biosciences
Fundamental company analysis:ASMB - Assembly Biosciences
Manufactured products of Assembly Biosciences Inc

Fundamental asset screening requires a precise assessment of a business's ability to generate real cash flow for security holders. By analyzing the net income per share over the last four quarters, an investor sees the final annual financial result divided by the total number of shares, which for Assembly Biosciences (ASMB) reflects the efficiency of patent monetization in hepatitis therapies and the resilience of its biopharmaceutical ecosystem.

Competitors of Assembly Biosciences

Arrowhead Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters mirumpharma.com MIRM|DVAX (Dynavax Corp) - Net earnings per share for the last 12 months|ABUS (Arbutus Biopharma Corp) - Earnings per share for the last twelve months|IVA (Inventiva Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Gyre Therapeutics Corp. GYRE|Earnings per share for the last twelve months Galectin Therapeutics (GALT)|GNFT (genfit.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) DRRX (DURECT)|Net earnings per share (EPS TTM) Aligos Therapeutics Inc. ALGS|BIVI - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Galmed Pharmaceuticals GLMD|ENDRA Life Sciences (NDRA) - Earnings per share for the last twelve months|HEPA - Net earnings per share for the last four quarters